Top

Breast Cancer Research and Treatment

Published in:

01-02-2011 | Letter to the editor

Comments on: Iwasaki et al. Fragment c gamma receptor gene polymorphisms and breast cancer risk in case–control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians

Author: Janardan P. Pandey

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Excerpt

To the Editor, …

Iwasaki M, Shimada N, Kasuga Y, et al (2010) Fragment c gamma receptor gene polymorphisms and breast cancer risk in case–control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Breast Cancer Res Treat. doi: 10.1007/s10549-010-1109-3

Jefferis R, Lefranc MP (2009) Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 1:332–338CrossRefPubMedPubMedCentral

Grubb R (1995) Advances in human immunoglobulin allotypes. Exp Clin Immunogenet 12:191–197PubMed

Iwasaki M, Shimada N, Kasuga Y et al (2010) Fragment c gamma receptor gene polymorphisms and breast cancer risk in case–control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Breast Cancer Res Treat. [Epub ahead of print]

Koene HR, Kleijer M, Algra J et al (1997) Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90:1109–1114PubMed

Salmon JE, Edberg JC, Brogle NL et al (1992) Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest 89:1274–1281CrossRefPubMedPubMedCentral

Pandey JP, Nietert PJ, Klaamas K et al (2009) A genetic variant of immunoglobulin gamma2 is strongly associated with immunity to mucin 1 in patients with breast cancer. Cancer Immunol Immunother 58:2025–2029CrossRefPubMed

Title: Comments on: Iwasaki et al. Fragment c gamma receptor gene polymorphisms and breast cancer risk in case–control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians
Author: Janardan P. Pandey
Publication date: 01-02-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1233-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2011

No association of polymorphisms in the cell polarity gene SCRIB with breast cancer risk in German population

Erratum to: A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma

The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells

Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

Keynote webinar | Spotlight on antibody–drug conjugates in cancer